Perspectives of therapeutical application of new purine nucleoside analogues;Perspektywy leczniczego zastosowania nowych analogów nukleozydów purynowych

Acta Haematologica Polonica

Volumn 39, Issue 4, 2008, Pages 727-741

  Korycka, Anna ^a,b  

^a Z Katedry i Kliniki Hematologii   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cladribine; Clofarabine; Fludarabine; Forodesine; Nelarabine; Purine nucleoside analogues

Indexed keywords

3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; ADENOSINE; ANTINEOPLASTIC AGENT; CLADRIBINE; CLOFARABINE; CYTOTOXIC AGENT; FLUDARABINE; FORODESINE; GUANOSINE; NELARABINE; PENTOSTATIN;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; CANCER RELAPSE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LYMPHOBLASTOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PROTEIN METABOLISM; REVIEW; T CELL LYMPHOMA;

EID: 59449087684     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203-2209.
2. Johnson, S.A. Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother 2001; 2: 929-943.
3. Dighiero G, Hamblin TJ. Chronic lymphocytic leuekmia. Lancet 2008; 371: 1017-1029.
4. Cortes J, Kantarjian H, Talpaz M. et al. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia 1997; 11: 788-791.
5. Robak T, Jamroziak K, Gora-Tybor J. et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007; 109: 3672-3675.
6. Robak T, Blonski JZ, Kasznicki M. et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723-2729.
7. Catovsky D, Richards S, Matutes FR. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia, (the LRF CLL4 Trial); a randomized control trial. Lancet 2007; 370: 230-239.
8. Zinzani PL. Non-Hodgkin's lymphoma: the evolving role of purine analogues. Best Pract Res Clin Haematol 2002; 15: 505-516.
9. Aldinucci D, Poletto D, Lorenzon D. et al. CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. Clin Cancer Res. 2004; 10: 508-520.
10. van Besien K, Artz A, Smith S. et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005; 23: 5728-5738.
11. Scott BL, Sandmaier BM, Storer B. et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128-135.
12. Schirmer M, Mur E, Pfeiffer KP, Thaler J, Konwalinka G. The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand J Rheumatol 1997; 26: 376-379.
13. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive ans antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006; 13: 3165- 3189.
14. Gandhi V, Kantarjian H, Faderl S. et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003; 9: 6335-6342.
15. Kisor DF, Plunkett W, Kurtzberg J. et al. Pharmacokinetics of nelarabine and 9-beta-D- arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 2000; 1: 995-1003.
16. Korycka A, Bloński JZ, Robak T. Forodesine (BCX-1777, Immucillin H)-a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem 2007; 7: 976- 983.
17. Kline JP, Larson R. Clofarabine in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia: a review. Expert Opin Pharmacother 2005; 6: 1-8.
18. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer 2005; 103: 1985-1995.
19. Jeha S, Gandhi V, Chan KW. et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784-789.
20. Berg SL, Blaney SM, Devidas M. et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005; 23: 3376-3382.
21. Korycka A, Lech-Maranda E, Robak T. Novel purine nucleoside analogues for hematological malignancies. Recent Patents on Anti-Cancer Drug Discovery. 2008; 3: 123-136.
22. Bantia S, Kilpatrick JM. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Discov Devel. 2004; 7: 243-247.
23. Bantia S, Miller PJ, Parker CD. et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent. Int Immunopharmacol 2001; 1: 1199-1210.
24. Galmarini, CM. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.Idrugs. 2006; 9: 712-722.
25. Balakrishnan K, Nimmanapalli R, Ravandi F, Keating M.J, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006,108: 2392-2398.
26. Parker WB, Secrist JA 3rd, Waud WR. Purine nucleoside antimetabolites in development for the treatment of cancer. Curr Opin Investig Drugs 2004; 5: 592-596.
27. Kisor DF. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. Ann Pharmacother 2005; 39: 1056 -1063.
28. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther 1991;49:239-268.
29. Van den Neste E, Cardoen S, Offner F, Bontemps F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine. Int J Oncol 2005; 27: 1113-1124.
30. King KM, Damaraju VL, Vickers MF. et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006; 69: 346-353.
31. Rose JB, Coe IR. Physiology of nucleoside transporters: back to the future.... Physiology (Be- thesda). 2008; 23: 41-48.
32. Wolowiec D, Benchaib M, Pernas P. et al. Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue. Leukemia. 1995; 9:1382-1388.
33. Robak T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev 2007; 33: 710-728.
34. Grütter MG. Caspases: key players in programmed cell death. Curr Opin Struct Biol 2000; 10: 649-655.
35. Genini D, Adachi S, Chao Q. et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-3543.
36. Prus KL, Averett DR, Zimmerman TP. Transport and metabolism of 9-beta-D- arabinofuranosylguanine in a human T-lymphoblastoid cell line nitrobenzylthioinosine-sensitive and - insensitive influx. Cancer Res 1990; 50: 1817-1821.
37. Rodriguez CO Jr, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phos- phorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 2002; 62: 3100-3105.
38. Kicska GA, Long L, Horig H, Fatrchild C, Tyler PC, Furneaux RH. et al.. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc. Natl. Acad. SCi USA. 2001; 98: 4593-4598.
39. Bonate PL, Craig A, Gaynon P. et al. Population pharmacokinetics of clofarabine, a seconfd generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Oncol. 2004; 44: 1309- 1322.
40. Kantarjian H, Gandhi V, Cortes J et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379-2386.
41. Cooper T, Kantarjian H Plunkett W, Gandhi V. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids. 2004; 23: 1417-1423.
42. Beesley AH, Palmer ML, Ford J et al. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2007; 137: 109-116
43. Gandhi V, Tarn C, O'Brien S. et al. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008; 26: 1098-1105.
44. Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S. i wsp. A proof-of- principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 2005; 106: 4253-4260.
45. Duvic M. From cell biology to therapy: forodesine. Hematol Meeting Reporst 2008; 2: 106-111.
46. Jeha S, Razzouk B, Rytting ME. et al. Phase II Trials of Clofarabine in Relapsed or Refractory Pediatric Leukemia. 46-th ASH Annual Meeting, San Diego, USA (2004).
47. Faded S, Gandhi V, O'Brien et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias Blood 2005; 105: 940 -947.
48. Karp JE, Ricklis RM, Balakrishnan K et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 15: 1762-1769.
49. Kurtzberg J, Ernst TJ. Keating MJ. et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005; 23: 3396-3403.
50. Gandhi V, Plunkett W, Weller S et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001; 19: 2142
51. Buie LW, Epstein SS, Lindley CM. Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 2007; 29: 1887-1899.
52. Furman RR, Iosava G, Isola L, Ravandi F, Zodelava, M. Bennett, J.C. Kilpatrick J.M. Bantia S. Forodesine (Fodosine™), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study). Blood. 2005; 106: 11, Abstr. 881
53. Duvic M, Forero-Torres A, Foss FM, Olsen EA, Kim Y. Oral Forodesine (BCX-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.Blood, 2006; 108, 11, Abstr. 2467
54. Ritchie E, Gore L, Roboz GJ, Feldman E, Ravandi F, Furman R. Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia. Blood. 2006; 108:11, Abstr 1881.